Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
All Comparisons

GHRP-2 vs Hexarelin

Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.

GHRP-2: CHexarelin: C
AttributeGHRP-2Hexarelin
CategoryGrowth Hormone SecretagogueGrowth Hormone Secretagogue
Evidence RatingCPhase I–II Clinical TrialsCPhase I–II Clinical Trials
Clinical StatusApproved in Japan for GH deficiency diagnosis; research-only elsewherePhase II completed. Development discontinued due to tolerance/desensitization concerns.
MechanismGHRP-2 (C45H55N9O6) binds to and activates ghrelin (GH secretagogue) receptors on pituitary somatotrophs, triggering robust pulsatile GH release. In healthy adults, 100 mcg SC daily produces acute GH stimulation. Unlike continuous GH, GHRP-2 maintains physiological feedback controls. Once-daily admi...Hexarelin binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus through a triple mechanism: direct stimulation of pituitary somatotroph cells to release stored GH, stimulation of hypothalamic GHRH-releasing neurons, and suppression of som...
Half-Life~15–60 minutes~70 minutes
Bioavailability
Molecular Weight~817.0 g/mol~887 g/mol
WADA StatusProhibitedProhibited
Research Half-Life~15–60 minutes~70 minutes
Key Use Cases
  • Body Composition
  • Body Composition
  • Anti-Aging
Safety Concerns
  • Well tolerated in clinical trials with placebo-like safety profile at therapeutic ranges
  • May increase appetite (less than GHRP-6)
  • Can elevate cortisol and prolactin levels (less than GHRP-6)
  • Generally well-tolerated in clinical trials
  • Transient cortisol and prolactin elevation at higher doses
  • Hunger increase (ghrelin receptor activation)
Contraindications
  • Active malignancy (GH/IGF-1 elevation contraindicated)
  • Pregnancy and breastfeeding
  • Pituitary disorders (outside diagnostic context)
  • Diabetes and cardiovascular conditions (GH affects glucose metabolism)
  • Active cancer (GH/IGF-1 axis stimulation)
  • Pituitary tumors
  • Pregnancy and breastfeeding
  • Diabetic retinopathy (GH may worsen)
Regulatory (US)Not FDA-approved. Research chemical only. Banned by WADA.Not FDA-approved. Development discontinued. Research chemical only.

Research Material Specifications

Catalog specifications for the corresponding research materials, including batch documentation coverage.

SpecificationGHRP-2Hexarelin
Purity Standard≥98%≥98%
CAS Number158861-67-7140703-51-1
Molecular FormulaN/AN/A
Available Formats10mg5mg
Batch COAs Published
Stock StatusOut of stockOut of stock

Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.

Explore More
Comparisons

Compare any two peptides side-by-side or browse our curated popular matchups.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.